Shanghai Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 5.147 billion yuan, a year-on-year increase of 26.96%

Shanghai Pharma released its third-quarter report for 2025, achieving operating revenue of 215.072 billion yuan from January to September 2025, a year-on-year increase of 2.60%. The net profit attributable to the parent company was 5.147 billion yuan, a year-on-year increase of 26.96%. The sales revenue of the pharmaceutical industry was 18.164 billion yuan, a year-on-year decrease of 0.66%; the sales revenue of the pharmaceutical business was 196.908 billion yuan, a year-on-year increase of 2.91%. After deducting one-time special gains and losses, the net profit attributable to the parent company was 3.979 billion yuan, a year-on-year decrease of 1.85%. The net cash flow from operating activities was 2.350 billion yuan, continuing to maintain high-quality development